Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting Quince Therapeutics, Inc. (Nasdaq: QNCX), ...

Patients with Friedreich’s ataxia experience progressive loss of coordination, muscle weakness, and fatigue, which commonly progresses to motor incapacitation and wheelchair reliance by their teens or ...

Friedreich ataxia patients struggle with timely diagnosis and access to specialized care due to the disease's rarity and complexity. Families and caregivers experience significant emotional and ...

Skyclarys activates the Nrf2 pathway which is involved in the cellular response to oxidative stress. The Food and Drug Administration (FDA) has approved Skyclarys ™ (omaveloxolone) for the treatment ...

Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its ...

Credit: Shutterstock. Elamipretide has been shown to improve frataxin levels in Friedreich ataxia patient-derived cells, and improve motor and cardiac function in an animal model of Friedreich ataxia.

Difficulty balancing or an inability to do so can be caused by any number of factors. Head injuries, migraines, alcohol use, ear infections and medications can all affect your musculoskeletal system ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of ...